Investor Relations

Registration Statement on Form F-4 – Preliminary Proxy Statement & Prospectus
The filing was made on June 21, 2021 with the with the U.S. Securities and Exchange Commission (“SEC”) in connection with Procaps Group and Union Acquisition Corp. II recently announced proposed business combination. The Registration Statement includes audited financials of Procaps Group for the full fiscal years of 2019 and 2020 and can be found here.

Investor Presentation May 2021

View Presentation

Second Quarter 2021 Results and Full Year 2021 Guidance

Add to Calendar View All Events

Company Overview

Procaps Group has experience in the development of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. We have direct presence in 13 countries in Latin America and we have more than 5,000 collaborators working under a sustainable model.

We develop, manufacture, and market over-the-counter (OTC) and prescription drugs, nutritional supplements and high-potential clinical solutions.

View Management Team View Board of Directors

Investor Contact Information

Company

Procaps Group
9 Rue de Bitbourg
L-1273 Luxembourg
Grand Duchy of Luxembourg